1.Ohgaki H, Kleihues P (2013) The definition of primary and secondary glioblastoma. Clin Cancer Res 19:764–772.doi:10.1158/1078-0432.CCR-12-3002
2.Jaoude DA, Moore JA, Moore MB, Twumasi-Ankrah P, Ablah E, Moore DF Jr. Glioblastoma and Increased Survival with Longer Chemotherapy Duration. Kans J Med. 2019;12(3):65-69. Published 2019 Aug 21.
3.Nobusawa S, Watanabe T, Kleihues P, Ohgaki H (2009) IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15:6002–6007.doi:10.1158/1078-0432.CCR-09-0715
4.Juratli TA, Kirsch M, Geiger K et al (2012) The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas. J Neurooncol 110:325–333. doi:10.1007/s11060-012-0977-2
5.Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu JJ, Henson JW, Engelhard HH, Chen TC, Tran DD, Sroubek J, Tran ND, Hottinger AF, Landolfi J, Desai R, Caroli M, Kew Y, Honnorat J, Idbaih A, Kirson ED, Weinberg U, Palti Y, Hegi ME, Ram Z. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA. 2015 Dec 15;314(23):2535-43. doi: 10.1001/jama.2015.16669. PMID: 26670971.
6.Yang W, Warrington NM, Taylor SJ, et al. Sex differences in GBM revealed by analysis of patient imaging, transcriptome, and survival data. Sci Transl Med. 2019;11(473):eaao5253. doi:10.1126/scitranslmed.aao5253
7.Matteoni S, Abbruzzese C, Villani V, et al. The influence of patient sex on clinical approaches to malignant glioma. Cancer Lett. 2020;468:41-47. doi:10.1016/j.canlet.2019.10.012
8.Yuan Y, Liu L, Chen H, et al. Comprehensive Characterization of Molecular Differences in Cancer between Male and Female Patients. Cancer Cell. 2016;29(5):711-722. doi:10.1016/j.ccell.2016.04.001
9.Minniti G, Armosini V, Salvati M, et al. Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma. J Neurooncol. 2011;103(3):683-691. doi:10.1007/s11060-010-0446-8
10.Jin MC, Liu EK, Shi S, Gibbs IC, Thomas R, Recht L, Soltys SG, Pollom EL, Chang SD, Hayden Gephart M, Nagpal S, Li G. Evaluating Surgical Resection Extent and Adjuvant Therapy in the Management of Gliosarcoma. Front Oncol. 2020 Mar 11;10:337. doi: 10.3389/fonc.2020.00337. PMID: 32219069; PMCID: PMC7078164.
11.Tully PA, Gogos AJ, Love C, Liew D, Drummond KJ, Morokoff AP. Reoperation for Recurrent Glioblastoma and Its Association With Survival Benefit. Neurosurgery. 2016 Nov;79(5):678-689. doi: 10.1227/NEU.0000000000001338. PMID: 27409404.
12.Simon M, Neuloh G, von Lehe M, Meyer B, Schramm J. Insular gliomas: the case for surgical management. J Neurosurg. 2009 Apr;110(4):685-95.doi:10.3171/2008.7.JNS17639. PMID: 19099379.
13.Jakola AS, Gulati S, Weber C et al (2011) Postoperative deterioration in health related quality of life as predictor for survival in patients with glioblastoma: A prospective study. PLoS ONE6:e28592. doi:10.1371/journal.pone.0028592.
14.Nam JY, de Groot JF. Treatment of Glioblastoma. J Oncol Pract. 2017 Oct;13(10):629-638. doi: 10.1200/JOP.2017.025536. PMID: 29020535.
15.Wang Z, Yang G, Zhang YY, Yao Y, Dong LH. A comparison between oral chemotherapy combined with radiotherapy and radiotherapy for newly diagnosed glioblastoma: A systematic review and meta-analysis. Medicine (Baltimore). 2017 Nov;96(44):e8444. doi: 10.1097/MD.0000000000008444. PMID: 29095287; PMCID: PMC5682806.d
16.Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009 Feb 19;360(8):765-73. doi: 10.1056/NEJMoa0808710. PMID: 19228619; PMCID: PMC2820383.
17.Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013;19(4):764-772. doi:10.1158/1078-0432.CCR-12-3002
18.Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005 Mar 10;352(10):997-1003. doi: 10.1056/NEJMoa043331. PMID: 15758010.
19.Binabaj MM, Bahrami A, ShahidSales S, Joodi M, Joudi Mashhad M, Hassanian SM, et al. The prognostic value of MGMT promoter methylation in glioblastoma: a meta-analysis of clinical trials. J Cell Physiol. 2018;233:378-386
20.Brell M, Tortosa A, Verger E, et al. Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res. 2005;11(14):5167-5174.doi:10.1158/1078-0432.CCR-05-0230